TATVA logo

Tatva Chintan Pharma Chem Limited Stock Price

NSEI:TATVA Community·₹29.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author

TATVA Share Price Performance

₹1,215.30
446.05 (57.99%)
₹1,390.00
Fair Value
₹1,215.30
446.05 (57.99%)
12.6% undervalued intrinsic discount
₹1,390.00
Fair Value
Price ₹1,215.30
AnalystConsensusTarget ₹1,390.00
AnalystLowTarget ₹535.00
AnalystHighTarget ₹1,710.00

TATVA Community Narratives

AnalystConsensusTarget·
Fair Value ₹1.39k 12.6% undervalued intrinsic discount

Overvaluation Risks And Emerging Sectors Will Shape Future Dynamics

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AnalystLowTarget·
Fair Value ₹535 127.2% overvalued intrinsic discount

Rising ESG Pressures And Localization Will Erode Export Outlook

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystHighTarget·
Fair Value ₹1.71k 28.9% undervalued intrinsic discount

Eco-friendly Specialty Chemicals Will Drive Global Market Expansion

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
₹1.39k
12.6% undervalued intrinsic discount
Revenue
22.95% p.a.
Profit Margin
13.07%
Future PE
41.84x
Price in 2029
₹2.09k
₹535
127.2% overvalued intrinsic discount
Revenue
20.9% p.a.
Profit Margin
7.67%
Future PE
36.61x
Price in 2028
₹780.03

Trending Discussion

Updated Narratives

TATVA logo

TATVA: Higher Future Multiple And Upcoming Results Will Support Bullish Outlook

Fair Value: ₹1.39k 12.6% undervalued intrinsic discount
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TATVA logo

TATVA: New CFO Appointment Will Support Governance And Future Earnings Quality

Fair Value: ₹1.71k 28.9% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TATVA logo

Rising ESG Pressures And Localization Will Erode Export Outlook

Fair Value: ₹535 127.2% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with high growth potential.

1 Risk
2 Rewards

Tatva Chintan Pharma Chem Limited Key Details

₹4.8b

Revenue

₹2.3b

Cost of Revenue

₹2.5b

Gross Profit

₹2.1b

Other Expenses

₹327.6m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
14.01
51.40%
6.83%
11.0%
View Full Analysis

About TATVA

Founded
1996
Employees
679
CEO
Chintan Shah
WebsiteView website
www.tatvachintan.com

Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants. The company serves automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors and fragrances sectors. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India.

Recent TATVA News & Updates

Tatva Chintan Pharma Chem Limited Just Beat EPS By 44%: Here's What Analysts Think Will Happen Next

Jan 24
Tatva Chintan Pharma Chem Limited Just Beat EPS By 44%: Here's What Analysts Think Will Happen Next

Recent updates

No updates